Approval · Notice of Compliance 27092 · 2021
SHINGRIX: Notice of Compliance 27092
Issued November 24, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27092
- Date
- November 24, 2021
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph and indication extension: SHINGRIX is indicated for the prevention of herpes zoster (HZ, or shingles) in: adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SHINGRIX | Not yet assigned | — |
Medicinal ingredients
- VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E (GE) 50 MCG per 0.5ML